C4XD C4x Discovery Holdings Plc

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Director/PDMR Share Purchases

9 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, was informed on 8 April 2024 that Clive Dix, Executive Chairman of the Company, purchased 485,320 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 10.3 pence per share.

Following this purchase of shares, Clive Dix has a beneficial interest in 2,071,809 Ordinary Shares, representing approximately 0.82 per cent. of the Company's issued share capital.

Further information on the purchases is contained in the disclosure tables below.

Contacts

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

Notes to Editors:

About C4X Discovery

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.